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 Supporting information for this article is given via a link at the end of the document. 
Abstract: Bioisosterism is an important concept in the lead optimisation phase of drug discovery where the aim is to make modifications to 
parts of a molecule to improve some properties while maintaining others. We present an analysis of bioisosteric fragments extracted from 1458 
ligands in an established data set taken from the Protein Data Bank and consisting of 121 protein targets. A pairwise analysis is carried out of 
all ligands for each target. The ligands are fragmented using the BRICS fragmentation scheme and a pair of fragments is deemed to be 
bioisosteric if the two fragments occupy a similar volume of the protein binding site. We consider two levels of generality, one which does not 
consider the number of attachment points in the fragments and a more restricted case in which both fragments are required to have the same 
number of attachments. We investigate the extent to which the bioisosteric pairs that are found are common across different targets.
Introduction 
Bioisosterism is an important concept in medicinal chemistry that 
can be traced back to the start of the last century.[1] The lead 
optimisation phase of drug discovery typically involves making 
structural modifications, or replacements, to parts of a molecule 
in order to modulate some properties while maintaining others. 
For example, the aim might be to increase metabolic stability or 
solubility without affecting biological activity. Structural changes 
or replacements that have a neutral effect on biological function 
are said to be bioisosteric.[1b] Bioisosteric replacements that 
involve replacing the core of a compound are often referred to as 
scaffold hops,[2] whereas those involving replacing the 
substituents on a core are often referred to as functional group 
replacements. Traditionally, the types of bioisosteric 
replacements that have been explored are based on a number of 
well-known bioisosteres, such as those first suggested by 
Thornber,[3] on the experience and expertise of medicinal 
chemists, or on a process of trial and error. A recent review of 
bioisosteres in drug design is provided by Meanwell who defines 
bioisosteres as classical or nonclassical.[4] Classical bioisoteres 
are represented by structurally simple fragment pairs typified by 
mono-, di- and trivalent atoms or groups and ring equivalents, 
whereas, nonclassical bioisosteres are structurally more distinct 
and often comprise of different numbers of atoms and include 
cyclic and noncyclic isosteres. Examples of functional groups 
commonly found in medicinal chemistry for which there is 
considerable interest in identifying nonclassical bioisosteric 
replacements include carboxylic acid,[5] which is present in a large 
number of drugs but is known to have issues related to metabolic 
instability and toxicity, and phosphate groups which are involved 
in many biological processes.[6] 
 
In recent years, significant effort has been devoted to identifying 
previously unknown bioisosteric replacements, to provide 
medicinal chemists with ideas that extend beyond their existing 
knowledge bases. The two main approaches have been the use 
of similarity methods and the application of data mining 
techniques to compound collections and the literature. Similarity 
methods are based on the similar property principle which states 
that similar molecules tend to have similar properties.[7] It is 
straight forward to extend the approach to comparing fragments 
and a variety of descriptors have been explored in the context of 
identifying bioisosteric fragments. For example, Ertl developed a 
web-based tool whereby a query substituent can be compared 
with a wide range of stored substituents based on 
physicochemical properties.[8] In another approach also based on 
physiochemical properties, Holliday et al.[9] developed the R-
Group descriptor which characterises substituents by atom-based 
physicochemical properties based on distance from the 
attachment point. The properties are summed over atoms at the 
same topological (that is, bond) distance from the substituent 
connection point and represented as a vector which can then be 
compared with the vector derived from a query substituent. 
Wagener and Lommerse[10] developed a method to compare 
fragments based on a topological pharmacophore fingerprint that 
is similar in concept to atom-pairs[11] in which through bond 
distances between pharmacophore features are recorded.  
Another 2D method includes the use of reduced graph 
representations which also focus on pharmacophoric features.[12] 
A comparison of 2D fingerprint similarity and 3D molecular field 
similarity to screen for bioisosteres was carried out by 
Schuffenhauer et al.[13] who demonstrated the complementarity of 
the approaches. 
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Data mining methods include manual and in-silico approaches. 
The BIOSTER database has been compiled though manual 
searching of the literature for pairs of molecules that exhibit similar 
activities and consists of some 28,000 structural modifications.[14] 
The in-silico data mining approaches include matched molecular 
SDLUV 003V ZKLFK VWHP IURP 6KHULGDQ¶V ZRUN LQ ZKLFK D
maximum common substructure algorithm is used to 
superimpose pairs of molecules that exhibit the same activity.[15] 
The common substructure is removed with the remaining 
substituents forming the bioisosteric groups. The recently 
published SwissBioisostere database consists of 4.5 million 
replacements that have been mined from ChEMBL using 
MMPs.[16]  
 
Data mining approaches have also been applied to protein-ligand 
complexes, which is the focus of the work described here. Watson 
et al. compared functional groups based on their interaction 
patterns to specific probe groups as observed in the Cambridge 
Structural Database.[17] Later, Kennewell et al. used 
crystallographic data to mine for target-specific bioisosteres.[18] 
Given a set of protein-ligand complexes for a given target, the 
complexes are first aligned based on the protein active sites and 
the aligned ligands are extracted. A reference ligand is chosen 
and all the ligands are fragmented. Each fragment of each ligand 
is then compared against the fragments in the reference and 
those with a high degree of volume overlap with reference 
fragments are assumed to have a similar role in the interaction 
with the target protein and defined as bioisosteric pairs. The 
method was used to identify target-specific bioisosteres for 12 
targets taken from the Protein Databank (PDB). Recently, Zhang 
et al. have used the Kennewell approach to identify potential 
structural replacements for phosphate groups.[19] As noted earlier, 
these are important in medicinal chemistry for a number of 
reasons including the high occurrence of ATP-binding proteins, 
however, they are underrepresented in the SwissBioisostere 
database.  
 
Other approaches based on protein ligand complexes include 
KRIPO and sc-PDB-Frag. In KRIPO, ligands extracted from PDB 
entries are fragmented with each fragment being used to define a 
local binding site. The local binding region is represented as a 
pharmacophore fingerprint and fragments that are associated 
with similar fingerprints, and therefore similar subpockets, are 
identified as potential bioisosteres. In the sc-PDB-Frag approach, 
bound ligands are fragmented and interaction fingerprints are 
calculated for each protein-fragment pair. A bioisostere is defined 
if a fragment pair has a low structural similarity and a high 
interaction pattern similarity. 
 
Bioisosteric replacements are often considered to be 
generalizable; that is, it is assumed that a similar effect may be 
seen regardless of the particular biological activity of interest. 
Wassermann and Bajorath[20] recently investigated whether 
bioisosteric replacements could be found that are preferential for 
a given target. They used MMPs to identify bioisosteres from 
25,000 ligands for 40 target families extracted from ChEMBL. A 
MMP is labelled as bioisosteric if it is found in more than one 
target in a family; if it occurs in different structural contexts; and if 
the potency difference in the ligands is moderate. Using these 
constraints, only 83 transformations were identified as bioisosteric, 
of which only 16 were found in more than one target family, with 
the majority, 67, being found in a single target only. As well as 
being target specific, bioisosteres have also been found to be 
context specific with respect to the structural environment in which 
they occur within the ligands themselves,[1a, 21] For example, in a 
recent review of carboxylic acid bioisosteres, Ballatore et al.[22] 
note the difficulty of accurately predicting the outcome of a 
particular isosteric replacement due to the context. 
 
AlthouJK:DVVHUPDQDQG%DMRUDWK¶VVWXG\ LVEDVHGRQD ODUJH
number of ligands and targets, the analysis uses 2D 
representations of the ligands only and does not take into account 
the structure of the protein. Thus, equivalences can be found 
between fragments which do not play similar roles when the 
ligands bind to their target. This is in contrast to the earlier study 
by Kennewell et al.[18] in which the orientation of the ligands within 
a binding site is taken into account and bioisosteres are defined 
as fragments that occupy similar volumes of the protein binding 
site. .HQQHZHOO¶V method was developed to identify target-specific 
bioisosteres, however, since their publication the number of 
structures deposited in the PDB has increased significantly thus 
presenting the opportunity to identify bioisosteres that are 
common across targets. Thus, the aim of this study is to apply 
.HQQHZHOO HW DO¶V PHWKRG WR D ODUJHU DQG PRUH GLYHUVH VHW RI
targets for which there are protein-ligand complexes in the PDB 
and to consider the extent to which bioisosteric pairs can be found 
that are common across those targets.  
Data set 
The data were taken from the AstraZeneca molecular overlays for 
pharmacophore validation[23] which comprises of 121 overlays of 
high-quality crystallographic structures available to download 
from the Cambridge Crystallographic Data Centre. Each overlay 
contains a set of ligands for a particular target that have been pre-
aligned based on the protein active sites. The total number of 
ligands available in the download is 1464, of which we were 
unable to process 6, leaving a total of 1458 ligands. The number 
of ligands per target in our set varies from 4 to 38 (with a mean 
number of 12). Figure 1 illustrates the overlay for the 17 ligands 
for the target Macrophage metalloelastase (Uniprot ID: P39900). 
The image shows all ligands in their three-dimensional orientation 
at the binding site. The full data set is shown in the Supporting 
Information which gives the Uniprot ID of the target protein, the 
target name, and the number of ligands in the target overlay. 
 
Figure 1. Overlay of ligands extracted from the target the Macrophage 
metalloelastase (Uniprot ID: P39900). 
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Methods 
The methods follow those described by Kennewell et al. starting 
from the point at which the aligned ligands have already been 
extracted from the proteins, since these were directly available in 
the pharmacophore validation set. An overview of the algorithm 
used to generate bioisosteric pairs from a set of overlaid ligands 
for a given target site is illustrated in Figure 2. Suppose a ligand 
overlay contains three ligands, A, B, and C. First, ligand A is taken 
as the reference ligand and fragmented into a set of three 
fragments {a1, a2, a3}. The remaining ligands in the overlay are 
treated as the query ligands. For example, let B be the first query 
ligand, which is fragmented to produce a set of three fragments 
{b1, b2, b3}. The algorithm then compares the fragments of ligand 
A with the fragments of ligand B. All the fragments in B, are scored 
by their volume overlap with the first fragment in ligand A, a1. If 
the overlap with fragment from B, b1 for example, is greater than 
a given threshold then {a1,b1} forms a bioisosteric pair, as defined 
by Kennewell et al. As the pair of fragments is found to occupy 
the same volume of the active site in the receptor it is assumed 
that both fragments play an equivalent role and are thus labelled 
as bioisosteres. The algorithm then compares the remaining 
fragments of B against A before moving on to the fragments of C. 
In Figure 3 the algorithm has already moved to molecule C and 
found two bioisosteric pairs {a1,b1} and {a1,c2}. Once the 
processing of A is complete, the next molecule is taken as 
reference, B in this case, and its fragments compared with the 
fragments in all other molecules. This process may or may not 
result in {b1,c2} also being identified as a pair, depending on the 
overlap threshold that is used. 
  
 
Figure 2. Illustration of the algorithm used to find bioisosteric pairs. 
In our work, three different fragmentation schemes were 
considered initially. These are: an implementation of the 
fragmentation scheme from Kennewell et al. with both 
overlapping and non-overlapping fragments; a modification in 
which fragments were limited to non-overlapping fragments; and 
the retrosynthetic fragmentation scheme BRICS[24] with non-
overlapping frDJPHQWV,Q.HQQHZHOO¶VDSSURDFKHDFKOLJDQGZDV
made the reference ligand in turn and compared against all other 
ligands in the set. Each reference ligand was split into what the 
DXWKRUVFDOOHG³VHFWLRQV´ZKLFKDUHQRQ-overlapping fragments of 
the ligand. In contrast, each query ligand was fragmented into a 
set of overlapping fragments. Each query fragment was then 
                                                 
1
 The SMARTS used was '[!$([NH]!@C(=O))&!D1&!$(*#*)]-
&!@[!$([NH]!@C(=O))&!D1&!$(*#*)]¶ 
compared against each section of the reference ligand. The 
overlapping fragments were generated by cutting single, non-ring, 
non-terminal bonds. In our implementation, a SMARTS 
representation of rotatable bonds 1 was used to search for the 
bonds to be broken. The bonds were then broken to form both a 
set of non-overlapping fragments and a set of overlapping 
fragments. In the case of the non-overlapping fragmentation, 
each molecule had all the identified bonds broken simultaneously 
to produce a disjoint set of fragments that constituted the original 
ligand, as illustrated in Figure 3(a). A set of overlapping fragments 
was generated by breaking one bond at a time to produce two 
fragments and repeating this recursively until there were no 
remaining bonds to break. The collection of fragments generated 
forms the set of overlapping fragments for each ligand, Figure 3(b).  
 
BRICS fragmentation builds on the popular RECAP fragmentation 
method and uses fragmentation rules that are based on 
retrosynthesis,[25] with the aim of producing synthetically relevant 
fragments. The BRICS fragmentation scheme uses a set of 13 
rules modified from the original RECAP set to obtain a more 
diverse fragment space.[24] The RDKit implementation of the 
BRICS scheme was used with the 13 rules encoded as SMARTS 
expressions and used to generate non-overlapping fragments. 
The non-overlapping fragments found using BRICS are illustrated 
in Figure 3(c).  
  
Figure 3. A ligand from target P39900 that has been fragmented according to 
D .HQQHZHOO¶V non-RYHUODSSLQJ IUDJPHQWDWLRQ VFKHPH E .HQQHZHOO¶V
overlapping fragmentation scheme; and (c) the BRICS non-overlapping 
fragmentation scheme. 
A comparison of the three fragmentation schemes shows that the 
overlapping method produces the largest number of fragments 
and may therefore give the greatest opportunity for finding 
bioisoteric pairs, however, it was thought that these fragments do 
Bioisosteric Pairs
Score	overlap
c1
0.7
Fragment	molecules
c2
b1 b2 b3
a1 a2 a3
c1 c2
b1 b2 b3
a1 a2 a3
a1 a1b1 c2
a1
c2
(a)
(b)
(c)
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not accord with the notion of fragments as used in lead 
optimisation. The BRICS retrosynthetic scheme, on the other 
hand, fragments molecules on bonds that can be made through 
known reactions so that the resultant fragments will be more 
meaningful to synthetic chemists. For this reason, the non-
overlapping BRICS fragmentation method was adopted for the 
experiments reported here.  
 
The volume overlap for each fragment pair was calculated using 
a simplified Gaussian function, again following Kennewell et al. 
For each atom, m, in the reference fragment, the Euclidean 
distance to each atom, n, in the query fragment is determined and 
a contribution to the score is calculated. The contributions are 
summed over all pairs of atoms and an average score calculated 
as shown below. The average score was calculated to account for 
size bias,  ݏܿ݋ݎ݁ ൌ ʹ݉ ൅ ݊෍෍݁ିௗ೔ǡೕమ௡௜ୀଵ௠௝ୀଵ  
where m and n are the numbers of atoms in the reference and 
query fragments, respectively, and a pair of fragments with a 
score greater than 0.7 was kept. The analysis was conducted at 
two levels: one in which the number of attachments points in each 
fragment was not considered and also at a more restricted level 
whereby the number of attachment points in each fragment 
should be the same. Thus, at the more general level, a pair of 
fragments is considered bioisosteric if they occupy a similar 
volume within the binding site of the target, and at the more 
restricted level the fragments must also have the same number of 
attachment points to the ligands from which they have been 
extracted. 
Results and Discussion 
Table 1 summarises the results for all 121 targets in the 
pharmacophore validation data set.  The 1458 ligands resulted in 
a total of 6282 fragments when summed across all targets. 55076 
fragment pairs were found by first identifying the unique pairs for 
each target and then summing across all targets. Of these, 3212 
represent bioisosteric pairs, that is, they pass the volume overlap 
threshold, with this number reducing to 1851 when the condition 
that the number of attachment points in each fragment must be 
equal is applied. Figure 4 gives an illustration of how these 
numbers were calculated. A summary of the results for each 
target is shown in the Supporting Information and example 
bioisosteres are shown in Figure 5. 
 
Table 1. See Figure 4 for an illustration of how these numbers were calculated. Note that Number of fragments, Number of fragment pairs and Number of bioisoteric 
pairs are summed over all targets. 
Number of 
targets 
Number of 
ligands 
Number of 
fragments 
Number of 
fragment 
pairs 
Number of 
bioisosteric 
pairs 
Number of 
cross target 
bioisosteric 
pairs 
Number of 
bioisosteric 
pairs ± 
equal 
number of 
attachments 
Number of 
cross target 
bioisosteric 
pairs - equal 
number of 
attachments 
121 1458 6282 55076 3212 146 1851 107 
 
 
Figure 4. Schematic to illustrate how the numbers shown in Table 1 were calculated. 
 
Number	of	fragments
per	target
Ligands Number	of	fragment	
pairs	per	target
Number	of	bioisosteric
pairs	per	target
Cross	target	
bioisosteric pairs
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Figure 5. Example bioisosteric pairs from targets: methionine aminopeptidase (P0AE18); bromodomain-containing protein 2 (P25440); and carbonic anhydrase II 
(P00918). 
 
Given the much larger number of targets in this study compared 
WR .HQQHZHOO HW DO¶V, the frequency of occurrence of each 
bioisosteric pair across the different targets was also determined. 
The occurrence of a given bioisosteric pair in more than one target 
would provide evidence of the generalisability of the 
transformation beyond a given target. Bioisosteric pairs from 
different targets were considered the same if they had identical 
topological structures. A summary of the results for the more 
general level (that is, when the number of attachment points is not 
taken into account) is presented in Figure 6 where the vertical axis 
of the graph is the number of bioisosteric pairs that were found in 
a given number of targets (log scale) and the horizontal axis is the 
number of targets. The vast majority of the bioisosteric pairs 
occurred in a single target with only 146 bioisosteric pairs found 
in more than one target. 106 bioisosteric pairs occurred in two 
targets only, with this number declining rapidly: 17 were found in 
three targets; and only 23 were found in more than three targets. 
The graph can be interpreted as a measure of the generalisability 
of the bioisosteres found using the BRICS-fragmentation method: 
the horizontal axis shows the increasing generality of the 
bioisosteres and the vertical axis shows the extent to which the 
bioisosteric pairs can be generalised across a diverse number of 
targets. All bioisosteric pairs that were found in three or more 
targets are shown in Figure 7 where it can be seen that those that 
occur in the largest number of targets tend to be small fragments 
or phenyl rings with different substitution patterns. All pairs found 
in more than one target are shown in the Supporting Information. 
For the more restricted case, only 107 bioisosteric pairs were 
found in more than one target; 82 of these occurred in two targets; 
10 were found in three targets; and only 13 were found in more 
than three targets. 
 
  
Figure 6. The frequency of occurrence of bioisosteric pairs across multiple 
targets.
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Figure 7. Bioisosteric pairs that were found in three or more targets. The number of targets is indicated in the top left corner of each cell.  
Conclusions 
Our results demonstrate that the vast majority of the bioisosteric 
pairs found using this method are unique to a single target. We 
found little evidence of bioisosteric pairs that are common across 
different targets within the PDB. Where we did find cross-target 
bioisosteres these were mostly common to two targets only, with 
those that were found in more than two targets being dominated 
by small classical fragments or phenyl rings with different 
substitution patterns. The lack of generalisability of the 
bioisosteres was a somewhat surprising finding given that 
functional group replacements are the cornerstone of lead 
optimisation programmes and our expectation that medicinal 
chemists tend to explore similar functional group replacements 
across different drug discovery projects. However, these results 
are consistent with the much larger study carried out by 
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Wassermann and Bajorath[20] in which the ligands and targets 
were extracted from ChEMBL and the analysis did not take into 
account the context of the target binding sites. 
 
It should be noted that this type of analysis is highly dependent 
on the fragmentation scheme used. In our case we chose to use 
the BRICS fragmentation scheme which results in a smaller 
number of fragments than would be found with the approach used 
in the original Kennewell method. This fragmentation method can 
also lead to some closely related fragments (for example, that 
differ in the number of atoms attached to a functional group) being 
identified as distinct, whereas, a medicinal chemist might see 
these as the same functional group. These effects undoubtedly 
had an effect on the number of bioisosteric pairs that were found, 
however, we feel that this scheme is likely to produce fragment 
pairs that are more meaningful to synthetic chemists. One issue 
with the BRICS scheme is that it does not fragment fused rings 
which could lead to an imbalance in the sizes of fragments within 
a pair. Finally, and as also noted by Wassermann and Bajorath, 
this analysis is affected by data sparseness so that it cannot be 
concluded that the presence of a bioisosteric pair in only one 
target means that it is specific to that target. It would therefore be 
interesting to repeat the study in the future as new structures are 
added to the PDB. 
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A data set of high quality protein-ligand complexes spanning 121 protein targets was analysed for the presence of bioisosteric fragments. 
A pairwise analysis of all ligands for each target was carried out. The ligands were fragmented and a pair of fragments considered 
bioisosteric if they occupy a similar volume of the protein binding site. Only a small number of the bioisosteric pairs were found to be 
common to two or more targets.
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